Cynata Therapeutics Ltd
ASX:CYP
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| AU |
|
Cynata Therapeutics Ltd
ASX:CYP
|
80.2m AUD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
383.2B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
197.2B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
181.9B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
119.9B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
81.7B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
88.9B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
44.4B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -16 177 900% |
| 30th Percentile | -544.7% |
| Median | -27.7% |
| 70th Percentile | 3.1% |
| Max | 3 174 540% |
Other Profitability Ratios
Cynata Therapeutics Ltd
Glance View
Cynata Therapeutics Ltd. engages in the development and commercialization of therapeutic products. The firm is engaged in the development and commercialization of a mesenchymal stem cell (MSC) technology for human therapeutic use, which the Company has branded as Cymerus. The Cymerus technology facilitates the manufacture of MSCs from a single donor and a single donation, which enables the development of therapeutic stem cell products. The firm's Cymerus platform stem cell technology is based upon stem cells known as mesenchymoangioblasts (MCAs). Its technology utilizes induced pluripotent stem cells (iPSCs) originating from an adult donor as the starting material for generating MCAs and in turn for manufacturing the MSC therapeutic product. The Company’s lead product candidate, CYP-001, which has met all clinical endpoints and demonstrated safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase I trial.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Cynata Therapeutics Ltd is -4 124.1%, which is below its 3-year median of -3 375.6%.
Over the last 3 years, Cynata Therapeutics Ltd’s Net Margin has decreased from -77.8% to -4 124.1%. During this period, it reached a low of -5 320.8% on Dec 31, 2022 and a high of -77.8% on May 30, 2022.
